Aduro BioTech Inc (NASDAQ:ADRO) VP Blaine Templeman sold 2,884 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $8.25, for a total transaction of $23,793.00. Following the completion of the transaction, the vice president now owns 69,937 shares in the company, valued at approximately $576,980.25. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Blaine Templeman also recently made the following trade(s):
- On Friday, November 17th, Blaine Templeman sold 243 shares of Aduro BioTech stock. The shares were sold at an average price of $8.85, for a total transaction of $2,150.55.
Aduro BioTech Inc (NASDAQ:ADRO) traded down $0.03 during midday trading on Friday, reaching $8.07. 348,600 shares of the company’s stock were exchanged, compared to its average volume of 420,193. Aduro BioTech Inc has a 52-week low of $6.01 and a 52-week high of $14.05.
A number of hedge funds and other institutional investors have recently bought and sold shares of ADRO. Legal & General Group Plc boosted its holdings in Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 1,043 shares during the period. Fox Run Management L.L.C. bought a new stake in Aduro BioTech in the 3rd quarter valued at about $127,000. SG Americas Securities LLC bought a new stake in Aduro BioTech in the 3rd quarter valued at about $167,000. Trexquant Investment LP bought a new stake in Aduro BioTech in the 3rd quarter valued at about $175,000. Finally, Voya Investment Management LLC lifted its holdings in shares of Aduro BioTech by 15.3% during the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 2,515 shares during the period. 45.19% of the stock is owned by hedge funds and other institutional investors.
ADRO has been the topic of a number of research reports. Oppenheimer initiated coverage on shares of Aduro BioTech in a research note on Monday, October 30th. They issued a “buy” rating and a $15.00 price target on the stock. HC Wainwright set a $18.00 price target on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Tuesday, October 17th. BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. William Blair reiterated an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Finally, Canaccord Genuity set a $30.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Aduro BioTech presently has an average rating of “Buy” and a consensus price target of $17.71.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/22/blaine-templeman-sells-2884-shares-of-aduro-biotech-inc-adro-stock.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.